1. Home
  2. TCI vs ADCT Comparison

TCI vs ADCT Comparison

Compare TCI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TCI
  • ADCT
  • Stock Information
  • Founded
  • TCI 1983
  • ADCT 2011
  • Country
  • TCI United States
  • ADCT Switzerland
  • Employees
  • TCI N/A
  • ADCT N/A
  • Industry
  • TCI Real Estate
  • ADCT Biotechnology: Pharmaceutical Preparations
  • Sector
  • TCI Finance
  • ADCT Health Care
  • Exchange
  • TCI Nasdaq
  • ADCT Nasdaq
  • Market Cap
  • TCI 388.8M
  • ADCT 380.2M
  • IPO Year
  • TCI N/A
  • ADCT 2020
  • Fundamental
  • Price
  • TCI $46.50
  • ADCT $4.10
  • Analyst Decision
  • TCI
  • ADCT Strong Buy
  • Analyst Count
  • TCI 0
  • ADCT 6
  • Target Price
  • TCI N/A
  • ADCT $7.60
  • AVG Volume (30 Days)
  • TCI 1.4K
  • ADCT 863.7K
  • Earning Date
  • TCI 11-18-2025
  • ADCT 11-10-2025
  • Dividend Yield
  • TCI N/A
  • ADCT N/A
  • EPS Growth
  • TCI 11.20
  • ADCT N/A
  • EPS
  • TCI 0.76
  • ADCT N/A
  • Revenue
  • TCI $47,730,000.00
  • ADCT $77,246,000.00
  • Revenue This Year
  • TCI N/A
  • ADCT $11.78
  • Revenue Next Year
  • TCI N/A
  • ADCT $4.83
  • P/E Ratio
  • TCI $57.94
  • ADCT N/A
  • Revenue Growth
  • TCI N/A
  • ADCT 15.73
  • 52 Week Low
  • TCI $25.50
  • ADCT $1.05
  • 52 Week High
  • TCI $48.00
  • ADCT $4.80
  • Technical
  • Relative Strength Index (RSI)
  • TCI 57.94
  • ADCT 48.88
  • Support Level
  • TCI $44.28
  • ADCT $3.88
  • Resistance Level
  • TCI $45.00
  • ADCT $4.80
  • Average True Range (ATR)
  • TCI 0.58
  • ADCT 0.23
  • MACD
  • TCI 0.15
  • ADCT -0.06
  • Stochastic Oscillator
  • TCI 73.05
  • ADCT 23.78

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: